Welcome to Psychiatryai.com: Latest Evidence - RAISR4D

Estimated reading time for CME/CPD: 2 mins

Clozapine Augmentation Strategies and Clinical Predictors of Prolonged Tertiary Hospitalization in Clozapine-Resistant Schizophrenia: a Retrospective Cohort Study

AI Summary
  • D2/3R selective antagonism was linked to shorter hospital stays than ECT, indicating greater resource efficiency.
  • ECT produced significantly greater improvement in positive symptoms compared with selective antagonism and partial agonism.
  • Higher admission psychosis severity and functional impairment predicted ECT at discharge, supporting measurement-based care to guide augmentation selection.
Summarise with AI (MRCPsych/FRANZCP)

Schizophr Bull. 2026 Oct 27;52(6):sbag187. doi: 10.1093/schbul/sbag187.

ABSTRACT

BACKGROUND AND HYPOTHESIS: Clozapine-resistant schizophrenia (CRS) remains a major clinical challenge, with persistent symptoms and functional impairment despite adequate clozapine treatment. Real-world evidence is limited, and guidelines recommend a narrow set of augmentation strategies-aripiprazole (D2/3R partial agonist), amisulpride (D2/3R selective antagonist), and electroconvulsive therapy (ECT)-without clear guidance on selection or sequencing. This study examined augmentation choice and its association with length of stay (LOS) and symptomatic outcomes.

STUDY DESIGN: We conducted a retrospective cohort study using BC Psychosis Program electronic records (2012-2025). Symptom severity and functioning scores (PANSS, CGI-S, GAPS, SOFAS) were extracted at admission and discharge. Multivariable Cox models assessed LOS for index and discharge augmentation strategies. ANCOVA compared symptom change across discharge strategies. A machine-learning model examined predictors of ECT versus pharmacological augmentation at discharge.

STUDY RESULTS: Eighty-eight admissions were included. In adjusted index models, D2/3R selective antagonism was associated with shorter LOS than ECT (HR 2.50, 95% CI 1.35-4.62); partial agonism was not (HR 1.41, 95% CI 0.75-2.63). Partial agonist augmentation had the highest inefficacy-related switching. By discharge strategy, ECT was associated with greater reduction in positive symptoms than selective antagonism (MD -3.20, 95% CI -5.65 to -0.75) and partial agonism (MD -3.87, 95% CI -6.57 to -1.16). Greater impairment in psychosis and functioning on admission predicted ECT at discharge (AUC 0.74; balanced accuracy 0.72).

CONCLUSIONS: D2/3R selective antagonism was the most resource-efficient strategy, while ECT produced greater improvement in positive symptoms. Incorporating baseline psychosis severity and functioning into measurement-based care may support more informed augmentation selection.

PMID:42951688 | DOI:10.1093/schbul/sbag187

Document this CPD

Share Evidence Blueprint

QR Code

Save to Google Notes

Search Google Scholar

Save as PDF

⭐ My Revision List

close chatgpt icon
ChatGPT

Enter your request.

← →
RAISR4D CME/CPD Evidence Nodes
Swipe to navigate RAISR4D CME/CPD evidence nodes.
CME/CPD